{"product_id":"amili-enhanced-gut-microbiome-test","title":"AMILI Enhanced Gut Microbiome Test","description":"\u003cdiv style=\"background: #f8f9fa; border-left: 4px solid #0057a8; padding: 12px 16px; margin-bottom: 20px;\" id=\"ai-summary\"\u003e\n\u003cstrong\u003eClinical Summary:\u003c\/strong\u003e The AMILI Enhanced Gut Microbiome Test is a Singapore-developed, at-home stool collection diagnostic that profiles intestinal bacterial composition using validated 16S rRNA gene sequencing. Results are interpreted against the largest multi-ethnic Asian gut microbiome reference database (GUTOMICS™), providing population-relevant insights across digestion, immunity, metabolism, and gut-brain axis function. The test produces a clinician-grade report with personalised dietary, lifestyle, and probiotic recommendations within 4-5 weeks of sample receipt.\u003c\/div\u003e\n\u003ch2\u003eProduct Overview\u003c\/h2\u003e\n\u003cp\u003eThe AMILI Enhanced Gut Microbiome Test is a precision-medicine diagnostic developed by AMILI Pte Ltd, a Singapore-headquartered microbiome biotechnology company spun out from the Singapore Stool Bank. It applies next-generation 16S rRNA gene amplicon sequencing to a single self-collected stool specimen to enumerate the relative abundance of bacterial taxa colonising the lower gastrointestinal tract. Unlike Western-derived microbiome panels, AMILI benchmarks each sample against GUTOMICS™, a proprietary database of more than 10,000 multi-ethnic Asian gut microbiomes curated in collaboration with A*STAR and regional clinical partners.\u003c\/p\u003e\n\u003cp\u003eThe Enhanced report quantifies four core functional axes derived from peer-reviewed metagenomic literature: Digestive Health (short-chain fatty acid producers, fibre fermenters), Immunity \u0026amp; Inflammation (regulatory taxa, opportunistic pathogen markers), Metabolic Health (bile acid metabolism, glucose homeostasis indicators), and Brain Health (gut-brain axis modulators including serotonin precursors). Each parameter is contextualised against age-, sex-, and ethnicity-matched cohorts. The clinician version of the report provides actionable dietary fibre prescriptions, prebiotic targets, and a personalised AMILI probiotic strain recommendation calibrated to the patient's deficiency profile.\u003c\/p\u003e\n\u003ch2\u003eTechnical Specifications\u003c\/h2\u003e\n\u003ctable style=\"border-collapse: collapse; width: 100%;\" cellspacing=\"0\" cellpadding=\"6\" border=\"1\"\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003cth align=\"left\"\u003eManufacturer\u003c\/th\u003e\n\u003ctd\u003eAMILI Pte Ltd, Singapore\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth align=\"left\"\u003eTest Type\u003c\/th\u003e\n\u003ctd\u003eAt-home stool collection, laboratory-processed gut microbiome profiling\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth align=\"left\"\u003eSequencing Platform\u003c\/th\u003e\n\u003ctd\u003e16S rRNA gene amplicon sequencing (V3-V4 region) on Illumina platform\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth align=\"left\"\u003eReference Database\u003c\/th\u003e\n\u003ctd\u003eGUTOMICS™ multi-ethnic Asian gut microbiome reference (\u0026gt;10,000 samples)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth align=\"left\"\u003eFunctional Axes Reported\u003c\/th\u003e\n\u003ctd\u003eDigestion, Immunity \u0026amp; Metabolism, Brain Health, Probiotic Match\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth align=\"left\"\u003eSample Type\u003c\/th\u003e\n\u003ctd\u003eSingle stool specimen, stabilised in proprietary preservative buffer\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth align=\"left\"\u003eCollection Method\u003c\/th\u003e\n\u003ctd\u003eSelf-collection at home using supplied kit; courier or drop-off return\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth align=\"left\"\u003eSample Stability\u003c\/th\u003e\n\u003ctd\u003eUp to 14 days at ambient temperature once stabilised\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth align=\"left\"\u003eTurnaround Time\u003c\/th\u003e\n\u003ctd\u003e4-5 weeks from laboratory receipt to digital report\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth align=\"left\"\u003eEligible Age\u003c\/th\u003e\n\u003ctd\u003e5 years and above (gut microbiome maturation threshold)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth align=\"left\"\u003eQuality System\u003c\/th\u003e\n\u003ctd\u003eISO 15189-aligned laboratory workflow; ISO 13485 quality management\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth align=\"left\"\u003eRegulatory\u003c\/th\u003e\n\u003ctd\u003eHSA Singapore notified; CLIA-equivalent laboratory standards; data handling per Singapore PDPA\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth align=\"left\"\u003eReport Format\u003c\/th\u003e\n\u003ctd\u003eDigital PDF (patient and clinician versions) with personalised recommendations\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003ch2\u003eClinical Indications\u003c\/h2\u003e\n\u003cul\u003e\n\u003cli\u003eBaseline gut microbiome characterisation for patients with chronic digestive complaints (IBS, functional dyspepsia, chronic constipation, intermittent diarrhoea)\u003c\/li\u003e\n\u003cli\u003eWorkup for suspected gut-immunity dysregulation (recurrent infections, atopic dermatitis, allergic rhinitis, food intolerance)\u003c\/li\u003e\n\u003cli\u003eMetabolic health profiling in pre-diabetes, dyslipidaemia, or metabolic syndrome management\u003c\/li\u003e\n\u003cli\u003ePre- and post-intervention monitoring for dietary modification, antibiotic recovery, or targeted probiotic therapy\u003c\/li\u003e\n\u003cli\u003eAdjunct assessment in mood, sleep, and cognition concerns where the gut-brain axis is clinically relevant\u003c\/li\u003e\n\u003cli\u003eRoutine wellness screening as part of an integrated functional medicine or longevity programme\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch2\u003eFrequently Asked Questions\u003c\/h2\u003e\n\u003ch3\u003eWhy is an Asian reference database important for interpreting my results?\u003c\/h3\u003e\n\u003cp\u003eGut microbiome composition is strongly shaped by diet, ethnicity, and geography. Reference ranges built from European or North American cohorts systematically misclassify Asian samples because key fibre-fermenting taxa (e.g. Prevotella copri, Faecalibacterium prausnitzii) are present at different baseline abundances. AMILI's GUTOMICS™ database, validated in peer-reviewed studies with A*STAR, allows population-appropriate interpretation that is clinically defensible for Singaporean and broader Southeast Asian patients.\u003c\/p\u003e\n\u003ch3\u003eIs 16S rRNA sequencing clinically reliable?\u003c\/h3\u003e\n\u003cp\u003e16S rRNA gene sequencing is the established methodology for genus- and family-level bacterial profiling, recommended by the Human Microbiome Project and used in over 30,000 published studies. It does not resolve to strain level (which requires whole-genome shotgun sequencing) but is appropriate, cost-effective, and reproducible for the functional reporting AMILI delivers. Laboratory workflows are aligned with ISO 15189 medical laboratory standards.\u003c\/p\u003e\n\u003ch3\u003eHow does this differ from a stool culture or faecal calprotectin test?\u003c\/h3\u003e\n\u003cp\u003eStool culture detects only a narrow range of culturable pathogens; faecal calprotectin quantifies neutrophil-derived inflammation. The AMILI Enhanced test profiles the entire bacterial community at relative-abundance level, enabling assessment of dysbiosis patterns, diversity indices (Shannon, Simpson), and functional capacity that conventional microbiology cannot reveal. It complements rather than replaces these established assays.\u003c\/p\u003e\n\u003ch3\u003eIs the test reimbursable under Singapore Medisave or private insurance?\u003c\/h3\u003e\n\u003cp\u003eThe AMILI Enhanced Gut Microbiome Test is a wellness diagnostic and is generally not Medisave-claimable. Some private integrated shield plans and corporate wellness programmes (including the Manulife-AMILI partnership) provide partial reimbursement; patients should confirm coverage with their insurer and obtain a referral letter from a registered Singapore medical practitioner where required.\u003c\/p\u003e\n\u003ch3\u003eHow should the report be acted upon clinically?\u003c\/h3\u003e\n\u003cp\u003eReports are designed for review with a qualified healthcare provider, registered dietitian, or naturopath. AMILI provides clinician onboarding materials and a Singapore-based scientific advisory team. Recommendations should be integrated with full clinical history, dietary assessment, and existing pharmacotherapy; the test is not a substitute for diagnostic endoscopy, imaging, or pathogen-specific assays where indicated.\u003c\/p\u003e","brand":"Amili","offers":[{"title":"Default Title","offer_id":43232608321614,"sku":null,"price":350.0,"currency_code":"SGD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0613\/3763\/2846\/files\/AMILI_Enhanced_Gut_Microbiome_Test_13356eae-7a55-4a77-a3e2-dc8a16aed9de.png?v=1767038461","url":"https:\/\/www.emis.asia\/zh\/products\/amili-enhanced-gut-microbiome-test","provider":"EMIS +","version":"1.0","type":"link"}